Aiphagan addition to prostaglandin analogue(PG) and/or beta-blocker and/or carbonic anhydrase inhibitor in normal pressure glaucoma study

Not Applicable

• Conditions: ormal tension glaucoma

• Registration Number: JPRN-UMIN000012582
• Lead Sponsor: AABC study group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2013-03-14
• Study Start: 2013-12-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Not provided

Exclusion Criteria

1.Complications with chronic or recurrent uveitis,scleritis,or corneal herpes. 2.History of ocular trauma or intraocular conventional surgery or laser ocular surgery in the study eye within 3 months before baseline examinations. 3.Any abnormality preventing reliable applanation tonometer in the study eye. 4.Known medical history of allergic to PGAs or beta-blockers. 5.Contraindication of betablockers. 6.Patients using an IOP-lowering drug other than those to be used in the study. 7.Patients using systemic administration of an oral CAI (Diamox,etc.). 8.Patient having serious eyes complications. 9.Women who are pregnant or lactating. 10.Severe dementia 11.Patients who are judged to be inappropriate for participation in the study for other reason by the doctor in charge.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy IOP value;IOP-lowering effect from baseline (reduced value;reduction rate%)

Secondary Outcome Measures

Name	Time	Method
Safety 1.Ocular safety assessment: Conjunctival hyperemia,adverse events 2.Systemic safety assessment: Blood pressure,the pulse,adverse events